1-苯基-4,5,6,7-四氢-1H-吲唑 | 14714-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-苯基-4,5,6,7-四氢-1H-吲唑
• 英文名称: 1-phenyl-4,5,6,7-tetrahydro-1H-indazole
• 英文别名: 1-phenyl-4,5,6,7-tetrahydroindazole；1-phenyl-4,5,6,7-tetrahydro-1H-indazole；1-Phenyl-4,5,6,7-tetrahydro-1H-indazol；1-Phenyl-4,5,6,7-tetrahydro-indazol
• CAS: 14714-06-8
• 化学式: C₁₃H₁₄N₂
• mdl: MFCD11501481
• 分子量: 198.268
• InChiKey: ZGBVBTYRFINFCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-苯基-4,5,6,7-四氢-1H-吲唑 在 palladium on activated charcoal 、 萘烷 作用下， 生成 1-苯基-1H-吲唑
  参考文献：
  名称：

  Notes: Preparation of Indazoles and Quinazolines by Catalytic Dehydrogenation

  摘要：

  DOI：

  10.1021/jo01103a611
• 作为产物：
  描述：

  1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid 生成 1-苯基-4,5,6,7-四氢-1H-吲唑
  参考文献：
  名称：

  v. Auwers, Justus Liebigs Annalen der Chemie, 1927, vol. 453, p. 228

  摘要：

  DOI：

文献信息

• Exploiting Synergistic Catalysis for an Ambient Temperature Photocycloaddition to Pyrazoles
  作者：Christopher P. Lakeland、David W. Watson、Joseph P. A. Harrity

  DOI：10.1002/chem.201904210

  日期：2020.1.2

  Sydnone-based cycloaddition reactions are a versatile platform for pyrazole synthesis, however they operate under harsh conditions (high temperature and long reaction times). Herein we report a strategy that addresses this limitation utilizing the synergistic combination of organocatalysis and visible-light photocatalysis. This new approach proceeds under ambient conditions and with excellent levels

  基于Sydnone的环加成反应是吡唑合成的通用平台，但是它们在苛刻的条件下（高温和长反应时间）运行。本文中，我们报告了一种利用有机催化和可见光光催化的协同组合解决这一局限性的策略。这种新方法在环境条件下进行，并且具有极好的区域控制能力。机理研究表明，光敏的sydnones（而不是烯胺）是成功实施该过程的关键。
• A robust protocol for Pd(ii)-catalyzed C-3 arylation of (1H) indazoles and pyrazoles: total synthesis of nigellidine hydrobromide
  作者：Mengchun Ye、Andrew J. F. Edmunds、James A. Morris、David Sale、Yejia Zhang、Jin-Quan Yu

  DOI：10.1039/c3sc50184a

  日期：——

  indazole and pyrazoles are privileged structural motifs in agrochemicals and pharmaceuticals. C-3 C-H arylation of (1H) indazole and pyrazole has been a significant challenge due to the poor reactivity of the C-3 position. Herein, we report a practical Pd(II)/Phen catalyst and conditions for direct C-3 arylation of indazole and pyrazole with ArI or ArBr without using Ag additives as halide scavengers. The

  C3-芳基吲唑和吡唑是农用化学品和药物中的优先结构基序。由于C-3位置的反应性较差，（1H）吲唑和吡唑的C-3 CH芳基化已成为一项重大挑战。在这里，我们报告了一种实用的Pd（II）/ Phen催化剂，以及吲哚和吡唑与ArI或ArBr进行直接C-3芳基化而不使用Ag添加剂作为卤化物清除剂的条件。发现使用甲苯，氯苯，三氟甲基苯和均三甲苯作为溶剂对于选择性和反应性至关重要。我们通过首次氢溴酸尼古丁的全合成以及与农药和药物分子结构相关的杂环的简便制备，进一步证明了该方案的稳健性。
• Palladium-catalyzed C–N bond formation: synthesis of 1-aryl-1H-pyrazoles from β-bromovinyl aldehydes and arylhydrazines
  作者：Chan Sik Cho、Daksha B. Patel

  DOI：10.1016/j.tet.2006.04.031

  日期：2006.6

  Cyclic and acyclic β-bromovinyl aldehydes are cyclized with an array of arylhydrazines in toluene at 125 °C in the presence of a palladium catalyst and a phosphorus chelating ligand together with NaOtBu to give 1-aryl-1H-pyrazoles in moderate to good yields.

  在钯催化剂和磷螯合配体以及NaO t Bu的存在下，在125°C下，用一系列芳基肼在甲苯中将环状和无环β-溴乙烯基醛环化，得到中度至中等浓度的1-芳基-1 H-吡唑良品率高。
• [EN] PROCESS FOR OBTAINING ENANTIOMERICALLY ENRICHED PYRAZOLE DERIVATIVES<br/>[FR] PROCÉDÉ D'OBTENTION DE DÉRIVÉS DU PYRAZOLE ENRICHIS EN ÉNANTIOMÈRES
  申请人：ESTEVE LABOR DR

  公开号：WO2010066829A1

  公开（公告）日：2010-06-17

  The present invention is directed to a process for the enantioselective hydrolysis of an ester of formula (I), which comprises reacting a mixture of C4-enantiomers of esters of formula (I), or salts thereof, with an esterase enzyme in the presence of a solvent. The invention is further directed to the transformation of said esters of formula (I) into enantiomerically enriched pyrazoles.

  本发明涉及一种手性选择性水解酯化合物(I)的方法，其中，在溶剂存在下，将酯化合物(I)的C4对映体混合物或其盐与酯酶酶反应。本发明还涉及将该化合物(I)转化为手性富集的吡唑化合物。
• FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0885883A1

  公开（公告）日：1998-12-23

  The present invention relates to a fused heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, and a medicament containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound of the present invention is a useful antipsychotic agent effective not only for positive symptoms centering on hallucination and delusion characteristic of the acute stage of schizophrenia, but also negative symptoms of apathy, abulia and autism. The inventive compound is expected to make a highly safe antipsychotic agent associated with less side effects, such as extrapyramidal symptoms and endocrine disturbance, which are observed when a conventional antipsychotic agent having a D2 receptor blocking action is administered. Therefore, the inventive compound can be used as a therapeutic agent for the diseases such as schizophrenia.

  本发明涉及式（I）的融合杂环化合物、其光学异构体、其药用盐、含有式（I）化合物、其光学异构体或其药用组合物的药物组合物。 其中各符号如说明书中所定义；其光学异构体；其药学上可接受的盐；含有式（I）化合物、其光学异构体或其药学上可接受的盐和药学上可接受的添加剂的药物组合物；以及含有式（I）化合物、其光学异构体或其药学上可接受的盐的药物。本发明的化合物是一种有用的抗精神病药物，不仅对精神分裂症急性期特有的以幻觉和妄想为中心的阳性症状有效，而且对冷漠、乏力和自闭等阴性症状也有效。本发明化合物有望成为一种高度安全的抗精神病药物，其副作用较小，如锥体外系症状和内分泌紊乱，这些副作用在使用具有 D2 受体阻断作用的传统抗精神病药物时会出现。因此，本发明化合物可用作精神分裂症等疾病的治疗药物。